Last reviewed · How we verify

NCT06322082: Incontinence

Pilates Training and Low Intensity Shock Wave Therapy for Post-prostatectomy Stress Incontinence

Status unknown NA Last updated 28 March 2024
What this trial tests

NA trial testing The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG) in Stress Incontinence, Male in 120 participants. Status unknown.

Timeline
20 March 2024
Primary endpoint
30 October 2024
15 December 2024

Quick facts

Lead sponsorKhadra Mohamed Ali
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment120
Start date20 March 2024
Primary completion30 October 2024
Estimated completion15 December 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Khadra Mohamed Ali

Who can join

Adults 40 to 75, male only, with Stress Incontinence, Male. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

120 Patients with urinary incontinence following radical prostatectomy would be randomly assigned to either 4 groups all receive conventional pelvic floor muscle exercises plus group A receive Pilates exercises and Low Intensity Extracorporeal Shock Wave Therapy, group B receive Low Intensity Extracorporeal Shock Wave Therapy, group C receive Pilates exercises and group D receive conventional pelvic floor muscle exercises. Assessment at baseline, immediately after the intervention, to evaluate the degree of urinary incontinence and quality of life after three months from treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Khadra Mohamed Ali trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06322082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing